BUSINESS
MSD Japan Embarking on 2-Step Spinoff for Women’s Health, Legacy Brands
February 28, 2020
After US Merck announced its spinoff plan earlier this month for women’s health, biosimilar, and legacy brand franchises, the New Jersey behemoth’s Japan unit is setting out to a two-step transition, envisaging the launch of…

LATEST

February 28, 2020
Takeda Pharmaceutical has exercised its option to acquire PvP Biologics as it took heart from PI proof-of-mechanism data from TAK-062, subject to their “build to buy” deal inked a few years back, the Japanese company said on February 26.Under thedeal…
February 28, 2020
The Japanese Association for Infectious Diseases compiled a paper on February 26 sharing its latest knowledge on the use of antivirals for the treatment of novel coronavirus disease (COVID-19).While noting that there is no drug approved that carries an indication…
February 28, 2020
Gilead Sciences said on February 26 that it is initiating two PIII clinical trials for its investigational antiviral remdesivir for the treatment of novel coronavirus disease (COVID-19), covering some 1,000 patients mainly across Asian countries.…
By Takamitsu Sasai

Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…

By Takashi Ebisawa

Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…

By Reiji Anasako

Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…

By Reiji Anasako

Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…

By Yoshinori Sagehashi

Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA